Share

Schrodinger Inc. - news published 227 - readings 2.892

BACK
Schrodinger Inc.

Schrodinger Inc.

Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda

Expects to Receive an Additional Distribution of Approximately $36 Million Related to Takeda's Upfront Payment in Second Quarter of 2023, for a Total Distribution of Approximately $147.3 Million NEW YORK--(BUSINESS WIRE)--Feb. 14, 2023-- Schrödinger Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovere ...

Continue reading
14.02.2023
Schrodinger Inc.

Schrodinger Inc.

Schrödinger to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 28

NEW YORK--(BUSINESS WIRE)--Feb. 13, 2023-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2022 financial results on Tuesday, February 28, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m ...

Continue reading
13.02.2023
Schrodinger Inc.

Schrodinger Inc.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Jan. 20, 2023-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on January 16, 2023, the company granted (i) non-statutory stock options to purchase an aggregate of 14,300 shares of the company's common stock to six newly hired employe ...

Continue reading
20.01.2023
Schrodinger Inc.

Schrodinger Inc.

Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities

New Target Added to Ongoing Collaboration with Bristol Myers Squibb Unveils LRRK2 Inhibitor Program Targeting Neurodegenerative Diseases New Collaboration and Software Agreement with Otsuka Pharmaceutical Co., Ltd. NEW YORK--(BUSINESS WIRE)--Jan. 9, 2023-- Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and ma ...

Continue reading
09.01.2023
Schrodinger Inc.

Schrodinger Inc.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Dec. 16, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on December 15, 2022, the company granted non-statutory stock options to purchase an aggregate of 26,350 shares of the company's common stock to seven newly hired employee ...

Continue reading
16.12.2022
Schrodinger Inc.

Schrodinger Inc.

Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting

Preclinical Data Highlight Strong Monotherapy Anti-Tumor Activity Across Multiple Acute Myeloid Leukemia Models and Combination Potential with Other Agents On Track to Submit Investigational New Drug Application for SGR-2921 to the U.S. Food and Drug Administration in the First Half of 2023 NEW YORK--(BUSINESS WIRE)--Dec. 12, 2022-- Schrödinger , Inc. (Nasdaq: SDGR), whose ph ...

Continue reading
12.12.2022
Schrodinger Inc.

Schrodinger Inc.

Schrödinger to Present at Piper Sandler 34th Annual Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Nov. 21, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. The presentation will take place on Tuesday, November 29, 2022, at 4:00 p ...

Continue reading
21.11.2022
Schrodinger Inc.

Schrodinger Inc.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Nov. 18, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on November 15, 2022, the company granted non-statutory stock options to purchase an aggregate of 32,165 shares of the company's common stock to eight newly hired employee ...

Continue reading
18.11.2022
Schrodinger Inc.

Schrodinger Inc.

Schrödinger to Present at Jefferies 13th Annual London Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Nov. 7, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies 13 th Annual London Healthcare Conference in London, UK. The presentation will take place on Wednesday, November ...

Continue reading
07.11.2022